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R20.995, p0.001 vs y1.04x-0.11, R20.97, p0.001), and it was much more
sensitive in detecting tissue prolapsed (100 vs 14 %, p0.01), thrombus (7 vs 0 %,
p0.01), dissection, mal-apposition qualitatively compared with IVUS.
Conclusions: This prospective multicenter study demonstrates that much more precise
evaluation can be expected in coronary lesion by OCT compared with IVUS even in vivo
in human. FD-OCT should be more reliable and feasible in the assessment of coronary
lesion morphology more than IVUS qualitatively and quantitatively in the clinical setting.
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Background: Confirming complete neointimal coverage after implantation of a drug-
eluting stent is clinically important because incomplete stent coverage is responsible for
late thrombosis and sudden cardiac death. Optical coherence tomography (OCT) is
emerging as a promising endovascular imaging tool for the evaluation of neointimal
response after drug-eluting stent implantation. This study used OCT to compare
neointimal response between Everolimus-eluting stents (EESs) and Sirolimus-eluting
stents (SESs).
Methods: RESET trial was a prospective dual-arm randomized trial of EESs and SESs
in 3197 patients with coronary artery disease. From the RESET trial, 90 patients (EES
54, SES  55) with 1-year follow-up OCT were investigated. Image analysis was
performed at 1-mm intervals.
Results: OCT identified 9591 struts in EESs and 9425 struts in SESs. The frequency of
stent struts with neointimal coverage was significantly higher in EESs compared with
SESs (89% vs. 83%, p  0.001). The frequency of malapposed stent struts was
significantly lower in EESs compared with SESs (0.01% vs. 1%, p  0.001). Averaged
neointimal thickness (128 	/ 53 m vs. 124 	/ 73 m, p  0.751) and neointimal
volume (25.71 	/ 14.11 mm3 vs. 23.90 	/ 17.56 mm3, p  0.555) was similar in
EESs and SESs. Thrombus was observed in 2% of EESs and 11% of SESs (p  0.113).
Conclusions: In this OCT subanalysis from RESET trial, neointimal coverage was
incomplete in both EESs and SESs at 1-year after stent implantation. Uncovered struts and
malapposed struts were less observed in EESs compared with SESs.
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Background: Recent clinical trials have demonstrated that intensive lipid-lowering
therapy by statins could prevent recurrent cardiac events after acute coronary syndrome
(ACS). Optical coherence tomography (OCT) is capable of estimating fibrous cap
thickness (FCT) of coronary atherosclerotic plaques, which might be associated with
plaque instability. This study was a prospective, randomized, open-label, dual-center
study to compare the effect of intensive vs. moderate statin therapy on FCT by using OCT.
Methods: A total of 56 ACS patients with dyslipidemia [low-density lipoprotein
cholesterol (LDL-C) levels100 mg/dL] were enrolled in this study. After percutaneous
coronary intervention (PCI), the patients were randomly assigned to two groups: intensive
statin therapy (atorvastatin 20 mg/day, n27) or moderate statin therapy (atorvastatin 5
mg/day, n25). OCT was performed to measure FCT in non-culprit intermediate lesions
at baseline and 12-month follow-up. Serum profiles of LDL-C, high density lipoprotein
cholesterol (HDL-C), high sensitive C-reactive protein (hs-CRP), malondialdehyde LDL
(MDA-LDL) and metalloproteinase-9 (MMP-9) were measured before PCI and at
12-month follow-up.
Results: Serum LDL cholesterol levels were significantly decreased in patients with
intensive statin therapy (132.7 	/ 28.2 to 70.5 	/ 13.4 mg/dL, -45.4 	/ 13.0%)
compared with moderate statin therapy (129.3 	/ 31.3 to 84.9 	/ 23.8 mg/dL, -33.2
	/ 18.1%) (p 0.02). FCT was significantly increased in patients with intensive statin
therapy (119.4 	/ 46.9 to 193.0 	/ 76.0 m, 66.2 	/ 40.9%) compared with
moderate statin therapy (118.0	/ 44.3 to 142.2	/ 69.2 m, 19.8	/ 32.9%) (p
0.001). The change of FCT had a significant negative correlation with the changes in
LDL-C (r -0.49, p 0.001) and MDA-LDL (r -0.32, p 0.02), while there was no
correlation between the changes of FCT and HDL-C (r  0.06, p  0.68). Furthermore,
the change in FCT showed a negative correlation with the changes in hs-CRP (r -0.30,
p  0.03) and MMP-9 (r  -0.57, p  0.001).
Conclusions: This OCT study suggests that the intensive lipid-lowering therapy with 20
mg/day of atorvastatin might be more helpful to stabilize coronary atheros.
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Background: Favorable effects on progression of coronary atherosclerosis contribute to
the ability of statins to reduce cardiovascular events. While statins have been proposed to
also stabilize atherosclerotic plaque by lowering LDL-C level and various pleiotropic
effects, this has not been well established in vivo. High resolution imaging with optical
coherence tomography (OCT) enables visualization of microstructures related to plaque
vulnerability. Therefore, the current study investigated the impact of statin therapy on
plaque microstructures by using OCT imaging.
Methods: 102 patients with coronary artery disease underwent OCT imaging of
non-culprit lipid-rich plaque. Patients treated with (n44) and without (n58) a statin
were compared with regard to clinical characteristics and OCT-derived features of plaque
vulnerability including fibrous cap thickness and microchannels. The impact of low
(n18) and high-dose (n26) statins on OCT measures was also compared.
Results: Statin-treated patients were more likely to be male (84% vs. 60%, p0.009) and
demonstrated lower leukocyte counts (77312900 /ul vs. 91423788 /ul, p0.04) than
patients without statin therapy. OCT demonstrated that statin-treated patients were less
likely to exhibit microchannels (46% vs. 68%, p0.03), in association with a greater
fibrous cap thickness (86.049.8um vs. 72.943.0um, p0.06). Especially, patients
treated with high-dose statin therapy were less likely to demonstrate microchannels than
patients treated with lower doses (39% vs. 59%, p0.01).
Conclusions: In the current study, use of statin therapy is associated with less vulnerable
plaque features on OCT imaging. Greater OCT evidence of plaque stabilization with high-dose
statin therapy is consistent with their favorable effects on cardiovascular outcomes.
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Background: The impact of intravascular ultrasound (IVUS) guided coronary drug
eluting stent (DES) implantation on clinical outcomes remains controversial. A meta-
analysis of the currently available clinical trials investigating IVUS guided DES
implantation was undertaken.
Methods: We searched Medline, the Cochrane Library and other internet sources,
without language or date restrictions for published articles comparing clinical outcomes
between IVUS- and angiography-guided DES implantation. Clinical studies with both
adjusted and unadjusted data were included.
Results: Nine studies were identified and included in the meta-analysis with a weighted
follow-up time of 21.711.8 months. Compared with angiography-guidance, IVUS-
guided DES implantation was associated with a reduced incidence of death (hazard ratio
[HR]: 0.58, 95% confidence interval [CI]: 0.47-0.71, p0.001), major adverse cardiac
events (HR: 0.85, 95% CI: 0.76-0.95, p0.005) and stent thrombosis (HR: 0.62, 95% CI:
0.46-0.83, p0.002). The incidence of myocardial infarction (HR: 0.80, 95% CI:
0.59-1.07, p0.134), target lesion (HR: 0.97, 95% CI: 0.76-1.23, p0.782) and target
vessel (HR: 0.94, 95% CI: 0.79-1.11, p0.455) revascularization were comparable
between the angiography and IVUS-guided arms. Repeat analyses in which the IVUS
guided and the angiography guided groups had similar baseline characteristics (apart from
older patients and more renal insufficiency in the angiography guided arm) (n9049), and
analyses with studies that were propensity matched (n4,128), yielded broadly similar
results in terms of clinical outcomes.
Conclusions: IVUS-guided coronary DES implantation is associated with a significant
reduction in death, MACE and stent thrombosis compared to angiography guidance.
Appropriately powered randomized trials are necessary to confirm the findings from this
meta-analysis.
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